A META-ANALYSIS OF PIPERACILLIN/TAZOBACTAM VERSUS CEFEPIME TREATMENT IN CANCER PATIENTS WITH FEBRILE NEUTROPENIA

被引:0
作者
Zhang Weidong [1 ]
Xiao Chun [2 ]
Zhou Sixin [3 ]
Wang Rui [1 ]
Wang Li [1 ]
Jia Liping [1 ]
Ma Jinqiu [1 ]
Wang Na [1 ]
机构
[1] First Hosp Qinhuangdao, Qinhuangdao 066000, Peoples R China
[2] PLA Rocket Force, Gen Hosp, Dept Gen Surg, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing 100853, Peoples R China
来源
BIOSCIENCE JOURNAL | 2016年 / 32卷 / 06期
关键词
Meta-analysis; Piperacillin/Tazobactam; Cefepime; Febrile neutropenia; Cancer; STEM-CELL TRANSPLANTATION; EMPIRICAL-TREATMENT; OPEN-LABEL; MONOTHERAPY; TAZOBACTAM; MULTICENTER; MANAGEMENT; THERAPY; FEVER; CHEMOTHERAPY;
D O I
暂无
中图分类号
S [农业科学];
学科分类号
09 ;
摘要
Febrile neutropenia (FN) causes a major threat to cancer patients after chemotherapy. Broad-spectrum antibiotic treatment is a well-established practice for febrile neutropenia. Piperacillin/Tazobactam (P/T) is the frequently used antibiotic in most of FN cases, whereas the use of cefepime remains unclear regarding its potential risk. However, little systematic analysis has been conducted about comparison between these two drugs. Thus, we undertook this meta-analysis to compare these two monotherapies for febrile neutropenia. Through searching Pubmed, Google scholar, Medline databases, EMBASE, OvidSP, ScienceDirect, Web of science, and China Journal Net (CJN) databases, we used the keywords "(Piperacillin/Tazobactam AND cefepime) AND (febrile neutropenia) AND (cancer or tumor)". Only studies with randomized controlled trials were included in the meta-analysis. We screened out a total number of seven clinical trials. This meta-analysis supported that P/T treatment was superior to cefepime treatment based on the average OR comparison, without statistical significance (OR = 1.27, 95% confidence interval = 0.98 to 1.64, p = 0.07). We further divided the seven studies into two subgroups based on age and treatment time. The young group (age <= 19) showed no significant difference (OR = 1.10, p = 0.65). While the old group (age > 19) showed that P/T treatment was better than cefepime with statistical difference (OR = 1.44, p = 0.05). The short-term group (time <= 3 ds) showed P/T treatment was better than cefepime with statistical difference (OR = 1.40, p = 0.05). While in the long-term group (time > 5 ds), there was no significant difference between P/T and cefepime therapy (OR = 1.06, p = 0.79) Asymmetry in Funnel plots indicated no publication bias (CHI2 = 1.47, I-2 = 0%, and p-value = 0.96) in this meta-analysis. It would be a good clinical trial to use P/T treatment to cure FN in cancer patients compared with cefepime treatment, especially in adult patients or patients with a short-term treatment period. This meta-analysis is practically important during antibiotic treatment in FN management.
引用
收藏
页码:1669 / 1678
页数:10
相关论文
共 50 条
  • [21] Cefepime Versus Cefepime Plus Amikacin as an Initial Antibiotic Choice for Pediatric Cancer Patients With Febrile Neutropenia in an Era of Increasing Cefepime Resistance
    Lee, Na Hee
    Kang, Ji-Man
    Lee, Ji Won
    Huh, Hee Jae
    Lee, Nam Yong
    Yoo, Keon Hee
    Sung, Ki Woong
    Koo, Hong Hoe
    Kim, Yae-Jean
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2020, 39 (10) : 931 - 936
  • [22] Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy
    José C Álvarez
    Sonia I Cuervo
    Javier R Garzón
    Julio C Gómez
    Jorge Augusto Díaz
    Edelberto Silva
    Ricardo Sánchez
    Jorge A Cortés
    BMC Pharmacology and Toxicology, 14
  • [23] Cefepime monotherapy for febrile neutropenia in patients with lung cancer
    Saito, Hiroshi
    Takahashi, Kosuke
    Okuno, Motoyasu
    Saka, Hideo
    Imaizumi, Kazuyoshi
    Hasegawa, Yoshinori
    Tanikawa, Yoshimasa
    Yamamoto, Masashi
    Taniguchi, Hiroyuki
    Shindoh, Joe
    Suzuki, Ryujiro
    Shimokata, Kaoru
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2014, 20 (5-6) : 365 - 369
  • [24] Piperacillin/Tazobactam Monotherapy Versus Piperacillin/Tazobactam Plus Amikacin as Initial Empirical Therapy for Febrile Neutropenia in Children with Acute Leukemia
    Zengin, Emine
    Sarper, Nazan
    Kilic, Suar Caki
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2011, 28 (04) : 311 - 320
  • [25] A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia
    Aynioglu, Aynur
    Mutlu, Birsen
    Hacihanefioglu, Abdullah
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2016, 29 (02) : 69 - 75
  • [26] Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients
    Kobayashi, Ryoji
    Hori, Daiki
    Sano, Hirozumi
    Suzuki, Daisuke
    Kishimoto, Kenji
    Kobayashi, Kunihiko
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2018, 51 (04) : 473 - 477
  • [27] Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia:: results of an open, randomized, multicentre trial
    Sanz, MA
    López, J
    Lahuerta, JJ
    Rovira, M
    Batlle, M
    Pérez, C
    Vázquez, L
    Julià, A
    Palau, J
    Gutiérrez, M
    Capote, FJ
    Ramos, F
    Benlloch, L
    Larrea, L
    Jarque, I
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (01) : 79 - 88
  • [28] Piperacillin/tazobactam versus carbapenems in patients with severe bacterial infections: A systematic review with meta-analysis
    Munch, Marie Warrer
    Granholm, Anders
    Jonsson, Andreas Bender
    Sjovall, Fredrik
    Helleberg, Marie
    Hertz, Frederik Botius
    Andersen, Jakob Steen
    Steensen, Morten
    Achiam, Michael Patrick
    Perner, Anders
    Moller, Morten Hylander
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2023, 67 (07) : 853 - 868
  • [29] Treatment of febrile neutropenia with cefepime monotherapy
    Jándula, BM
    Martino, R
    Gurgi, M
    Manteiga, R
    Sierra, J
    CHEMOTHERAPY, 2001, 47 (03) : 226 - 231
  • [30] Meropenem versus piperacillin/tazobactam for febrile neutropenia in pediatric patients: efficacy of piperacillin/tazobactam as a 1-h drip infusion four times a day
    Ryoji Kobayashi
    Hirozumi Sano
    Satoru Matsushima
    Daiki Hori
    Masato Yanagi
    Koya Kodama
    Daisuke Suzuki
    Kunihiko Kobayashi
    International Journal of Hematology, 2021, 113 : 430 - 435